Goodwin Advises Syndicate of Existing Investors on Microbiotica's £36 Million Series C Financing
The Life Sciences team advised Cambridge Innovation Capital, IP Group, Flerie Invest AB, and Seventure on the £36 million Series C financing for Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines. The financing was led by British Business Bank, and all existing Series B investors participated in the financing. Proceeds will support the advancement of MB310 into Phase 2 clinical development in ulcerative colitis, following positive results from the COMPOSER-1 Phase 1b study, which met its primary and secondary endpoints and demonstrated statistically significant improvements in clinical remission versus placebo.
Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category leading deep tech and life sciences companies. CIC currently manages in excess of £0.6 billion and has invested in around 40 companies. CIC is a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups.
IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, it develops and supports some of the world’s most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, IP Group backs world-changing innovation emerging in leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
Flerie is an active and long-term investor in life science, with a broad and diversified portfolio of innovative companies with groundbreaking technologies. It invests globally in companies focused on product development and commercial growth, together with other leading investors, and with a focus on hard-to-access private companies. Flerie's active ownership model, extensive networks, and resources are used to support and accelerate the development of the companies' projects, creating value for shareholders. Flerie AB's common stock is listed on Nasdaq Stockholm under the ticker FLERIE.
Seventure Partners is a long-term equity investor that actively supports innovative companies aiming to generate positive outcomes for people, society, sustainability and the planet. With approximately €1bn in commitments under management as of June 2026, Seventure is a leading European venture capital firm that has invested since 1997 in high-growth innovative companies across two main areas: (i) life sciences (e.g. biotechnology, healthcare and digital health, nutrition, foodtech, blue economy, aquaculture, animal health, agriculture, sport and wellness), with a particular focus on microbiome-related innovations across Europe, Asia and North America, and (ii) digital technologies (e.g. fintech, retailtech, cybersecurity) in Western Europe. Investment tickets range from €500k to €10M per round, and up to €20M per company, spanning seed, venture capital, growth, IPO, development capital and LBO stages.
The Goodwin deal team was led by Sophie McGrath and Matthew Shelley.
For more information about the deal, please read the press release.